Arcus Biosciences director granted RSUs and options
Arcus Biosciences director Nicole Lambert reported equity awards consisting of restricted stock units and stock options.
Rhea-AI Filing Summary
Arcus Biosciences director Nicole Lambert reported equity awards consisting of restricted stock units and stock options. On June 11, 2026, she received 5,700 shares of Common Stock as a grant, bringing her direct holdings to 43,000 shares.
She was also granted options to buy 16,900 shares at an exercise price of $23.30 per share, expiring on June 10, 2036. Both the 5,700 restricted stock units and the 16,900 options vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and each will become fully vested if the company undergoes a change in control.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 22,600 shares
Grant/Award
2 txns
Insider
Lambert Nicole
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,900 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,700 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,900 contracts (Direct);
Common Stock — 43,000 shares (Direct)
Footnotes (2)
- F1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
- F2. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Key Figures
RSU grant: 5,700 shares
Common shares held: 43,000 shares
Stock options granted: 16,900 options
+3 more
6 metrics
RSU grant
5,700 shares
Restricted stock units granted June 11, 2026, vesting by June 11, 2027 or next annual meeting
Common shares held
43,000 shares
Total Common Stock directly held by Nicole Lambert after the grant
Stock options granted
16,900 options
Options granted June 11, 2026, tied to Arcus Biosciences Common Stock
Option exercise price
$23.30 per share
Exercise price for the 16,900 stock options granted
Option expiration
June 10, 2036
Expiration date of the granted stock options
Vesting date
June 11, 2027
Latest vesting date for both RSUs and options, unless earlier at next annual meeting
Key Terms
restricted stock units, change in control, stock option, exercise price, +1 more
5 terms
restricted stock units financial
"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
change in control financial
"The RSUs will become fully vested in the event the Company is subject to a change in control."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
stock option financial
"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "23.3000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders financial
"vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Nicole Lambert receive in this Arcus Biosciences (RCUS) Form 4 filing?
Nicole Lambert received equity awards consisting of 5,700 shares of Common Stock and stock options for 16,900 shares. Both awards were reported as grants, rather than market purchases, and are tied to future vesting conditions and potential change in control of the company.
What are the key terms of Nicole Lambert’s stock option grant at Arcus Biosciences (RCUS)?
Nicole Lambert received stock options covering 16,900 shares with an exercise price of $23.30 per share, expiring June 10, 2036. These options vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and fully vest if the company undergoes a change in control.
When do Nicole Lambert’s restricted stock units in Arcus Biosciences (RCUS) vest?
The 5,700 restricted stock units vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders. According to the filing, they also become fully vested if Arcus Biosciences is subject to a change in control, accelerating the vesting schedule under that circumstance.
How does a change in control affect Nicole Lambert’s Arcus Biosciences (RCUS) awards?
Both the 5,700 restricted stock units and the 16,900 stock options become fully vested if Arcus Biosciences experiences a change in control. This means all units and options would vest immediately upon such an event, regardless of the normal vesting date or the timing of the next annual meeting.
Is Nicole Lambert’s transaction in Arcus Biosciences (RCUS) a market buy or sell?
The reported transactions are grants, not market purchases or sales. The Form 4 shows an acquisition coded as a grant or award of 5,700 shares of Common Stock and 16,900 stock options, both provided at no cash price per share on the grant date, with future vesting conditions attached.
AI-generated analysis. How Rhea-AI works. Not financial advice.
